HU-331 (CAS 137252-25-6)
See product citations (1)
Available in US only.
QUICK LINKS
HU-331 is a synthetic cannabinoid that has attention in the research community primarily for its potential as a compound with high affinity for cannabinoid receptors. It is particularly noted for its role in the study of the endocannabinoid system, a complex network of receptors, endogenous ligands, and enzymes that regulate a wide array of physiological processes. Researchers utilize HU-331 in investigations aiming to elucidate the effects of cannabinoids beyond the properties associated with tetrahydrocannabinol (THC). It acts as a potent inhibitor of topoisomerase II, an enzyme critical for DNA replication and cell cycle progression, making it useful in studies of cellular proliferation and gene expression. The compound′s unique structure allows scientists to examine the structural requirements for receptor binding and activity, contributing to the design of new molecules that can selectively interact with cannabinoid receptors.
HU-331 (CAS 137252-25-6) References
- A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. | Kogan, NM., et al. 2006. Mol Pharmacol. 70: 51-9. PMID: 16571653
- HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. | Kogan, NM., et al. 2007. Mol Cancer Ther. 6: 173-83. PMID: 17237277
- A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study. | Kogan, NM., et al. 2007. J Pharmacol Exp Ther. 322: 646-53. PMID: 17478614
- HU-331: a cannabinoid quinone, with uncommon cytotoxic properties and low toxicity. | Peters, M. and Kogan, NM. 2007. Expert Opin Investig Drugs. 16: 1405-13. PMID: 17714026
- Cannabidiol hydroxyquinone-induced apoptosis of splenocytes is mediated predominantly by thiol depletion. | Wu, HY. and Jan, TR. 2010. Toxicol Lett. 195: 68-74. PMID: 20184945
- Cyclohexa-2,5-diene-1,4-dione-based antiproliferative agents: design, synthesis, and cytotoxic evaluation. | Petronzi, C., et al. 2013. J Exp Clin Cancer Res. 32: 24. PMID: 23631805
- HU-331 is a catalytic inhibitor of topoisomerase IIα. | Regal, KM., et al. 2014. Chem Res Toxicol. 27: 2044-51. PMID: 25409338
- HU-331 and Oxidized Cannabidiol Act as Inhibitors of Human Topoisomerase IIα and β. | Wilson, JT., et al. 2018. Chem Res Toxicol. 31: 137-144. PMID: 29272108
- Monocyclic Quinone Structure-Activity Patterns: Synthesis of Catalytic Inhibitors of Topoisomerase II with Potent Antiproliferative Activity. | Waugh, TM., et al. 2020. ChemMedChem. 15: 114-124. PMID: 31778038
- Cannabinoid Quinones-A Review and Novel Observations. | Kogan, NM., et al. 2021. Molecules. 26: PMID: 33801057
- Cannabidiol oxidation product HU-331 is a potential anticancer cannabinoid-quinone: a narrative review. | Trac, J., et al. 2021. J Cannabis Res. 3: 11. PMID: 33892826
- Cannabinoids as Potential Cancer Therapeutics: The Concentration Conundrum. | Carkaci-Salli, N., et al. 2023. Cannabis Cannabinoid Res.. PMID: 36944160
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HU-331, 1 mg | sc-205345 | 1 mg | $107.00 | |||
| US: Only available in the US | ||||||
HU-331, 5 mg | sc-205345A | 5 mg | $837.00 | |||
| US: Only available in the US | ||||||